Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
- Received Investigational Device Exemption approval from the FDA for the use of Foresight CLARITY™ for patient enrollment in the ALPHA3 clinical trial - - Goals in 2025 include expanding biopharma partnerships and regulated use of Foresight CLARITY™, preparing for the commercialization of Foresight CLARITY™ in lymphoma, and establishing an LDT with real-time testing for solid tumors - BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic outlook for 2025 and a review of corporate highlights from the past year. "Foresight has achieved or exceeded 100% revenue growth every year since our founding, and in 2024 we reached significant clinical and regulatory milestones that further our mission of delivering innovative diagnostics for cancer patients," said Jake Chabon, Ph.D., CEO and co-founder of Foresight Diagnostics. "In 2025 we will prepar
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology [Yahoo! FinYahoo! Fin
- Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical OncologyGlobeNewswire
- Allogene Therapeutics Announces Participation in February Investor ConferencesGlobeNewswire
- Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical OfficerGlobeNewswire
- Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune DiseasesGlobeNewswire
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 2/18/25 - Form 144
- 2/14/25 - Form SCHEDULE
- 2/13/25 - Form SCHEDULE
- ALLO's page on the SEC website